🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

47 results for “UGA” Clear

  1. 12-Valent Pneumococcal Conjugate Vaccine

    MAIA Biotechnology

    Pneumococcal Vaccines

    phase 3 mab active

    1 trial

  2. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine

    Sanofi Pasteur

    Meningococcal infection

    phase 3 small molecule active

    1 trial

  3. Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

    Sanofi Pasteur

    Meningococcal Infection

    phase 3 mab completed

    1 trial

  4. Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine

    Sanofi Pasteur

    Meningococcal Immunization

    phase 3 mab completed

    1 trial

  5. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and s

    Sanofi Pasteur

    Healthy volunteers (Meningococcal infection)

    phase 3 small molecule active

    1 trial

  6. PREVNAR 20 ®, Pneumococcal Conjugate Vaccine (PCV)

    Sanofi-aventis Healthcare Pty Ltd

    Pneumococcal immunisation

    phase 3 small molecule active

    1 trial

  7. Placebo to Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6), Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6)

    Pfizer Australia Pty Ltd

    Group B streptococcus (GBS) disease

    phase 3 small molecule active

    1 trial

  8. Pneumovax® 23 solution for injection in pre-filled syringe Pneumococcal Polysaccharide Vaccine, V110, Pneumococcal 21-valent Conjugate Vaccine

    Merck Sharp and Dohme

    Pneumococcal disease

    phase 3 small molecule active

    1 trial

  9. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  10. Synthetic Conjugated estrogens, B

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  11. Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)

    Sanofi-aventis Healthcare Pty Ltd

    Pneumococcal Immunization

    phase 3 small molecule active

    1 trial

  12. batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)

    CanSino Biologics

    Meningococcal Meningitis

    phase 3 mab active

    1 trial

  13. conjugated estrogens

    Ultragenyx UK Limited

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  14. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  15. DTPw-HBV/Hib-MenAC conjugate vaccine

    GlaxoSmithKline

    Diphtheria

    phase 2 mab completed

    1 trial

  16. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi-aventis Healthcare Pty Ltd

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  17. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, DANICOPAN, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)

    Lacuna Pharma Pty Ltd

    Chronic spontaneous urticaria

    phase 2 small molecule active

    1 trial

  18. Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)

    BRIGHT MINDS BIOSCIENCES INC.

    Meningitis

    phase 2 mab active

    1 trial

  19. NicVAX conjugate vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 mab completed

    1 trial

  20. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  21. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  22. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  23. Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  24. Sugammadex Injection 2mg/kg

    BRIGHT MINDS BIOSCIENCES INC.

    Anesthesia, General

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources